CAMBRIDGE, England--(BUSINESS WIRE)--Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy ® for applications in early disease detection and precision medicine, today announced it has ...

CAMBRIDGE, England--(BUSINESS WIRE)--Owlstone Medical, a diagnostics company developing a breathalyzer for disease, today announced the launch of its Breath Biopsy® Kits, based on the company’s ...

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, announced that GSK, a world leader in respiratory, will incorporate Owlstone Medical’s Breath Biopsy platform into ...

But Owlstone Medical is taking a different route, working on a breath-based cancer detection system. The company hopes their technology will improve early detection and decrease false positives. They ...

Owlstone Medical has secured the first closing of its Series E financing round, securing $27m (approximately £22m) to advance the development of its Breath Biopsy platform and the commercialisation of ...

Owlstone Medical, the global leader in Breath Biopsy ® for applications in early disease detection and precision medicine, today announced the results of a patient study that successfully demonstrates ...

Cambridge-based Owlstone Medical has announced new results from a study of its breath-based diagnostic test for liver disease, including Nonalcoholic Fatty Liver Disease (NAFLD) and associated ...

Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that ...

Owlstone Medical has raised a total of $50 million for its Breath Biopsy platform. The Cambridge, England-based company said it has raised about $73 million since it was founded in 2016. The funds ...

Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy ® for applications in early disease detection and precision medicine, today announced that the Cystic Fibrosis Foundation has made an ...